6,963 publications from this institution
The purpose of the Benestent II Pilot Phase was to explore the safety of reducing antithrombotic therapy in conjunction with implantation of heparin-coated stents. The study consists of three phases, where resumption of heparin therapy after stent implantation was progressively delayed in a stepped care approach. Material and Methods Palmaz-Schatz stents with heparin coating were implanted in 51 patients (88% male) with stable angina pectoris. Heparin treatment was withheld 6 hours following removal of the sheath introducer from the femoral artery. The mean age was 59 years, 10% had a previous myocardial infarction, diabetes was prevalent in 8%, hypertension in 24% and 59% were current or previous smokers. Target lesion was located in the left anterior descending artery in 51%, left circumflex in 8% and right coronary artery in 41%. TIMI flow I-II was present in 14% and TIMI III in 86%. The mean pre-procedural minimal lumen diameter (MLD) was 1.10mm and reference diameter 3.16 mm. Results Stent implantation was successful in all patients and following the procedure, mean MLD increased to 2.77mm and percent diameter stenosis was reduced from 65% to 19%. The maximum balloon size was 3.45±0.40mm. Post-stent dilatation was performed in 40 patients (80%). High pressure (>12 atm) was used in 22 of these cases (54%). Two patients needed a second stent; one for an occlusive distal dissection and one for a distal lesion. There were no major complications, i.e. death, myocardial infarction, urgent CABG, re-PTCA or cerebrovascular accident. Peripheral vascular complications required vascular surgery in 3 patients (5.9%) and blood transfusion in one (2%). Conclusions In this pilot study implantation of heparinized stents was associated with a 100% success rate, absence of serious complications and a moderate incidence of vascular complications. Further reduction of antithrombotic treatment may be feasible.
Several mediators produced by various inflammatory cells have now been implicated in asthma. They may contribute to the pathology of asthma by contracting airway smooth muscle, stimulating mucus secretion, and promoting bronchial oedema and chemotaxis of inflammatory cells. Because many mediators interact, antagonism of any single mediator is unlikely to have a major clinical effect.
When tubular members are in bending, they tend to flatten towards the axis of bending, thus reducing their second moment of area. Eventually, a limit point is reached whereupon the initial stability of the system is lost and unstable equilibrium prevails, thus reducing the load carrying capacity of the member. This effect was originally described by Brazier (1927) for circular tubular members. In the present study, the analysis of Brazier is adapted for elliptical hollow section members, taking into account the additional geometric complexities inherent in ellipses. An analytical method is presented whereby the initial geometry and the displacement functions of the system are replaced by Fourier series, thus reducing the analytical complexity of the problem. After formulating the potential energy functional, use of a variational method allows for the amplitudes of the constituent harmonics of the Fourier approximations of the displacement functions to be solved for, providing estimates of the deformed geometry of the cross-section and the associated moment. In keeping with the analogy of Brazier for circular sections, a limit point is observed. These analytical predictions are then compared with the results of a complementary finite element analysis, whereupon it is found that for smaller longitudinal curvatures there is close agreement between the analytical and numerical methods. For larger curvatures and moments beyond the limit point some divergence is observed between the predictions of the two methods, which can be attributed to the lower-order approximations assumed in formulating the potential energy functional in the analytical method
"Cytokines as Mediators of Chronic Asthma." American Journal of Respiratory and Critical Care Medicine, 150(5_pt_2), pp. S42–S49